Adoptive T cell immunotherapy for cytomegalovirus

Expert Opinion on Biological Therapy

Volumn 9, Issue 6, 2009, Pages 725-736

  Peggs, Karl S ^a  

^a UNIVERSITY COLLEGE LONDON   (United Kingdom)

Author keywords

Cellular therapy; Cytomegalovirus; Foscarnet; Ganciclovir; Immune response; Transplantation

Indexed keywords

CYTOMEGALOVIRUS ANTIGEN PP65; CYTOMEGALOVIRUS VACCINE; DENDRITIC CELL VACCINE;

ADAPTIVE IMMUNITY; ADOPTIVE IMMUNOTHERAPY; ANTIGEN PRESENTING CELL; CD4+ T LYMPHOCYTE; CD8+ T LYMPHOCYTE; CELL LINE; CELL SELECTION; CLINICAL TRIAL; CYTOMEGALOVIRUS; CYTOMEGALOVIRUS INFECTION; CYTOTOXICITY; GRAFT VERSUS HOST REACTION; HUMAN; INFECTION PREVENTION; LYMPHOCYTE CLONE; NONHUMAN; REVIEW; STEM CELL TRANSPLANTATION; VACCINATION; VIRUS IMMUNITY; VIRUS REPLICATION;

CLINICAL TRIALS AS TOPIC; CYTOMEGALOVIRUS; CYTOMEGALOVIRUS INFECTIONS; HUMANS; IMMUNOTHERAPY, ADOPTIVE; T-LYMPHOCYTES;

CYTOMEGALOVIRUS;

EID: 67649101756     PISSN: 14712598     EISSN: None     Source Type: Journal    
DOI: 10.1517/14712590902967588     Document Type: Review

References (57)

1. Olsson J, Wikby A, Johansson B, et al. Age-related change in peripheral blood T-lymphocyte subpopulations and cytomegalovirus infection in the very old: the Swedish longitudinal OCTO immune study. Mech Ageing Dev 2000;121(1-3):187-201 (Pubitemid 32115413)
2. Wikby A, Johansson B, Olsson J, et al. Expansions of peripheral blood CD8 T-lymphocyte subpopulations and an association with cytomegalovirus seropositivity in the elderly: the Swedish NONA immune study. Exp Gerontol 2002;37(2-3):445-453 (Pubitemid 34073563)
3. Pawelec G, Derhovanessian E, Larbi A, et al. Cytomegalovirus and human immunosenescence. Rev Med Virol 2009;19(1):47-56
4. Khan N, Best D, Bruton R, et al. T cell recognition patterns of immunodominant cytomegalovirus antigens in primary and persistent infection. J Immunol 2007;178(7):4455-4465 (Pubitemid 46492397)
5. Sester M, Sester U, Gartner B, et al. Sustained high frequencies of specific CD4 T cells restricted to a single persistent virus. J Virol 2002;76(8):3748-3755 (Pubitemid 34250539)
6. Khan N, Shariff N, Cobbold M, et al. Cytomegalovirus seropositivity drives the CD8 T cell repertoire toward greater clonality in healthy elderly individuals. J Immunol 2002;169(4):1984-1992 (Pubitemid 34857662)
7. Khan N, Hislop A, Gudgeon N, et al. Herpesvirus-specific CD8 T cell immunity in old age: cytomegalovirus impairs the response to a coresident EBV infection. J Immunol 2004;173(12):7481-7489 (Pubitemid 39628188)
8. Pourgheysari B, Khan N, Best D, et al. The cytomegalovirus-specific CD4+ T-cell response expands with age and markedly alters the CD4+ T-cell repertoire. J Virol 2007;81(14):7759-7765 (Pubitemid 47047862)
9. Elkington R, Walker S, Crough T, et al. Ex vivo profiling of CD8+-T-cell responses to human cytomegalovirus reveals broad and multispecific reactivities in healthy virus carriers. J Virol 2003;77(9):5226-5240 (Pubitemid 36460937)
10. Waldrop SL, Davis KA, Maino VC, Picker LJ. Normal human CD4+ memory T cells display broad heterogeneity in their activation threshold for cytokine synthesis. J Immunol 1998;161(10):5284-5295 (Pubitemid 28519088)
11. Sylwester AW, Mitchell BL, Edgar JB, et al. Broadly targeted human cytomegalovirus-specific CD4+ and CD8+ T cells dominate the memory compartments of exposed subjects. J Exp Med 2005;202(5):673-685 •• Detailed dissection of breadth and fine specificity of anti-CMV responses in healthy volunteers, along with quantification of individual and total responses, demonstrating previously unrecognised diversity of human responses. (Pubitemid 41248418)
12. Nichols WG, Corey L, Gooley T, et al. Rising pp65 antigenemia during preemptive anticytomegalovirus therapy after allogeneic hematopoietic stem cell transplantation: risk factors, correlation with DNA load, and outcomes. Blood 2001;97(4):867-874 (Pubitemid 32154267)
13. Einsele H, Ehninger G, Hebart H, et al. Polymerase chain reaction monitoring reduces the incidence of cytomegalovirus disease and the duration and side effects of antiviral therapy after bone marrow transplantation. Blood 1995;86(7):2815-2820 • One of the first studies to establish the role of PCR in surveillance programmes allowing targeted anti-viral therapy.
14. Winston DJ, Young JA, Pullarkat V, et al. Maribavir prophylaxis for prevention of cytomegalovirus infection in allogeneic stem cell transplant recipients: a multicenter, randomized, double-blind, placebo-controlled, dose-ranging study. Blood 2008;111(11):5403-5410
15. Goodrich JM, Mori M, Gleaves CA, et al. Early treatment with ganciclovir to prevent cytomegalovirus disease after allogeneic bone marrow transplantation. N Engl J Med 1991;325(23):1601-1607
16. Goodrich JM, Bowden RA, Fisher L, et al. Ganciclovir prophylaxis to prevent cytomegalovirus disease after allogeneic marrow transplant. Ann Intern Med 1993;118(3):173-178 (Pubitemid 23034801)
17. Nichols WG, Corey L, Gooley T, et al. High risk of death due to bacterial and fungal infection among cytomegalovirus (CMV)-seronegative recipients of stem cell transplants from seropositive donors: evidence for indirect effects of primary CMV infection. J Infect Dis 2002;185(3):273-282 (Pubitemid 34107239)
18. Boeckh M, Leisenring W, Riddell SR, et al. Late cytomegalovirus disease and mortality in recipients of allogeneic hematopoietic stem cell transplants: importance of viral load and T-cell immunity. Blood 2003;101(2):407-414 (Pubitemid 36077556)
19. Junghanss C, Storb R, Maris MB, et al. Impact of unrelated donor status on the incidence and outcome of cytomegalovirus infections after non-myeloablative allogeneic stem cell transplantation. Br J Haematol 2003;123(4):662-670 (Pubitemid 37468063)
20. Boeckh M, Nichols WG. The impact of cytomegalovirus serostatus of donor and recipient before hematopoietic stem cell transplantation in the era of antiviral prophylaxis and preemptive therapy. Blood 2004;103(6):2003-2008 (Pubitemid 38326213)
21. Ljungman P, Brand R, Einsele H, et al. Donor CMV serologic status and outcome of CMV-seropositive recipients after unrelated donor stem cell transplantation: an EBMT megafile analysis. Blood 2003;102(13):4255-4260 (Pubitemid 37494081)
22. Rapp M, Messerle M, Buhler B, et al. Identification of the murine cytomegalovirus glycoprotein B gene and its expression by recombinant vaccinia virus. J Virol 1992;66(7):4399-4406
23. Cook M, Briggs D, Craddock C, et al. Donor KIR genotype has a major influence on the rate of cytomegalovirus reactivation following T-cell replete stem cell transplantation. Blood 2006;107(3):1230-1232 (Pubitemid 43156330)
24. Chen C, Busson M, Rocha V, et al. Activating KIR genes are associated with CMV reactivation and survival after non-T-cell depleted HLA-identical sibling bone marrow transplantation for malignant disorders. Bone Marrow Transplant 2006;38(6):437-444 (Pubitemid 44340375)
25. Zaia JA, Sun JY, Gallez-Hawkins GM, et al. The effect of single and combined activating killer immunoglobulin-like receptor genotypes on cytomegalovirus infection and immunity after hematopoietic cell transplantation. Biol Blood Marrow Transplant 2009;15(3):315-325
26. Reusser P, Riddell SR, Meyers JD, Greenberg PD. Cytotoxic T-lymphocyte response to cytomegalovirus after human allogeneic bone marrow transplantation: pattern of recovery and correlation with cytomegalovirus infection and disease. Blood 1991;78(5):1373-1380
27. Cwynarski K, Ainsworth J, Cobbold M, et al. Direct visualization of cytomegalovirus-specific T-cell reconstitution after allogeneic stem cell transplantation. Blood 2001;97(5):1232-1240 • Earliest study using HLA-tetramer technology to quantify reconstitution of CMV-specific T cells following allogeneic transplantation. (Pubitemid 32183744)
28. Aubert G, Hassan-Walker AF, Madrigal JA, et al. Cytomegalovirus-specific cellular immune responses and viremia in recipients of allogeneic stem cell transplants. J Infect Dis 2001;184(8):955-963 (Pubitemid 32955111)
29. Gratama JW, van Esser JW, Lamers CH, et al. Tetramer-based quantification of cytomegalovirus (CMV)-specific CD8+ T lymphocytes in T-cell-depleted stem cell grafts and after transplantation may identify patients at risk for progressive CMV infection. Blood 2001;98(5):1358-1364
30. Hebart H, Daginik S, Stevanovic S, et al. Sensitive detection of human cytomegalovirus peptide-specific cytotoxic T-lymphocyte responses by interferon-γ-enzyme-linked immunospot assay and flow cytometry in healthy individuals and in patients after allogeneic stem cell transplantation. Blood 2002;99(10):3830-3837 (Pubitemid 34534558)
31. Gratama JW, Brooimans RA, van der Holt B, et al. Monitoring cytomegalovirus IE-1 and pp65-specific CD4+ and CD8+ T-cell responses after allogeneic stem cell transplantation may identify patients at risk for recurrent CMV reactivations. Cytometry B Clin Cytom 2008;74B(4):211-220 (Pubitemid 352007318)
32. Reddehase MJ, Weiland F, Munch K, et al. Interstitial murine cytomegalovirus pneumonia after irradiation: characterization of cells that limit viral replication during established infection of the lungs. J Virol 1985;55(2):264-273 (Pubitemid 16239710)
33. Riddell SR, Watanabe KS, Goodrich JM, et al. Restoration of viral immunity in immunodeficient humans by the adoptive transfer of T cell clones. Science 1992;257(5067):238-241
34. Walter EA, Greenberg PD, Gilbert MJ, et al. Reconstitution of cellular immunity against cytomegalovirus in recipients of allogeneic bone marrow by transfer of T-cell clones from the donor. N Engl J Med 1995;333(16):1038-1044 •• First study demonstrating proof of principle for the ability of adoptive T cell therapies to hasten immune reconstitution in human subjects.
35. Einsele H, Roosnek E, Rufer N, et al. Infusion of cytomegalovirus (CMV)-specific T cells for the treatment of CMV infection not responding to antiviral chemotherapy. Blood 2002;99(11):3916-3922 (Pubitemid 35332029)
36. Peggs KS, Verfuerth S, Pizzey A, et al. Adoptive cellular therapy for early cytomegalovirus infection after allogeneic stem-cell transplantation with virus-specific T-cell lines. Lancet 2003;362(9393):1375-7 •• Demonstration of the potential for very low doses of CMV-specific T cells to expand enormously in vivo following adoptive transfer, with apparent restoration of durable protective immunity. (Pubitemid 37338339)
37. Micklethwaite K, Hansen A, Foster A, et al. Ex vivo expansion and prophylactic infusion of CMV-pp65 peptide-specific cytotoxic T-lymphocytes following allogeneic hematopoietic stem cell transplantation. Biol Blood Marrow Transplant 2007;13(6):707-714 (Pubitemid 46767999)
38. Cobbold M, Khan N, Pourgheysari B, et al. Adoptive transfer of cytomegalovirus-specific CTL to stem cell transplant patients after selection by HLA-peptide tetramers. J Exp Med 2005;202(3):379-386 •• Demonstration that selection based on HLA-multimers and transfer of CD8 T cells with highly restricted target specificty may result in enhanced immune reconstitution independent of CD4 T cell responses. (Pubitemid 41126955)
39. Rauser G, Einsele H, Sinzger C, et al. Rapid generation of combined CMV-specific CD4+ and CD8+ T-cell lines for adoptive transfer into recipients of allogeneic stem cell transplants. Blood 2004;103(9):3565-3572 (Pubitemid 38525695)
40. Mackinnon S, Thomson K, Verfuerth S, et al. Adoptive cellular therapy for cytomegalovirus infection following allogeneic stem cell transplantation using virus-specific T cells. Blood Cells Mol Dis 2008;40(1):63-67 (Pubitemid 350192302)
41. Szmania S, Galloway A, Bruorton M, et al. Isolation and expansion of cytomegalovirus-specific cytotoxic T lymphocytes to clinical scale from a single blood draw using dendritic cells and HLA-tetramers. Blood 2001;98(3):505-512
42. Fujita Y, Leen AM, Sun J, et al. Exploiting cytokine secretion to rapidly produce multivirus-specific T cells for adoptive immunotherapy. J Immunother 2008;31(7):665-674
43. Perruccio K, Tosti A, Burchielli E, et al. Transferring functional immune responses to pathogens after haploidentical hematopoietic transplantation. Blood 2005;106(13):4397-4406 (Pubitemid 41775954)
44. Heslop HE, Ng CY, Li C, et al. Long-term restoration of immunity against Epstein-Barr virus infection by adoptive transfer of gene-modified virus-specific T lymphocytes. Nat Med 1996;2(5):551-555 (Pubitemid 26150682)
45. Peggs K, Verfuerth S, Mackinnon S. Induction of cytomegalovirus (CMV)-specific T-cell responses using dendritic cells pulsed with CMV antigen: a novel culture system free of live CMV virions. Blood 2001;97(4):994-1000 (Pubitemid 32154284)
46. Peggs K, Verfuerth S, Pizzey A, et al. Characterization of human cytomegalovirus peptide-specific CD8+ T-cell repertoire diversity following in vitro restimulation by antigen-pulsed dendritic cells. Blood 2002;99(1):213-223 (Pubitemid 34532986)
47. Gattinoni L, Klebanoff CA, Palmer DC, et al. Acquisition of full effector function in vitro paradoxically impairs the in vivo antitumor efficacy of adoptively transferred CD8+ T cells. J Clin Invest 2005;115(6):1616-1626 (Pubitemid 40814670)
48. Leen AM, Myers GD, Sili U, et al. Monoculture-derived T lymphocytes specific for multiple viruses expand and produce clinically relevant effects in immunocompromised individuals. Nat Med 2006;12(10):1160-1166 • Demonstration of potential to transfer T cells with mutliple viral-specificities, providing a useful strategy in patients at particular risk from multiple pathogens. (Pubitemid 44527351)
49. Micklethwaite KP, Clancy L, Sandher U, et al. Prophylactic infusion of cytomegalovirus-specific cytotoxic T lymphocytes stimulated with Ad5f35pp65 gene-modified dendritic cells after allogeneic hemopoietic stem cell transplantation. Blood 2008;112(10):3974-3981
50. Keenan RD, Ainsworth J, Khan N, et al. Purification of cytomegalovirus-specific CD8 T cells from peripheral blood using HLA-peptide tetramers. Br J Haematol 2001;115(2):428-434 (Pubitemid 34203513)
51. Neudorfer J, Schmidt B, Huster KM, et al. Reversible HLA multimers (Streptamers) for the isolation of human cytotoxic T lymphocytes functionally active against tumor- and virus-derived antigens. J Immunol Methods 2007;320(1-2):119-131 (Pubitemid 46349106)
52. Assenmacher M, Lohning M, Radbruch A. Detection and isolation of cytokine secreting cells using the cytometric cytokine secretion assay. Curr Protoc Immunol 2002; Chapter 6:Unit 6.27
53. Feuchtinger T, Matthes-Martin S, Richard C, et al. Safe adoptive transfer of virus-specific T-cell immunity for the treatment of systemic adenovirus infection after allogeneic stem cell transplantation. Br J Haematol 2006;134(1):64-76 (Pubitemid 43830030)
54. Schleiss MR. Cytomegalovirus vaccines: at last, a major step forward. Herpes 2009;15(3):44-45
55. Pass RF, Zhang C, Evans A, et al. Vaccine prevention of maternal cytomegalovirus infection. N Engl J Med 2009;360(12):1191-1199
56. Grigoleit GU, Kapp M, Hebart H, et al. Dendritic cell vaccination in allogeneic stem cell recipients: induction of human cytomegalovirus (HCMV)-specific cytotoxic T lymphocyte responses even in patients receiving a transplant from an HCMV-seronegative donor. J Infect Dis 2007;196(5):699-704 (Pubitemid 47293851)
57. Park KD, Marti L, Kurtzberg J, Szabolcs P. In vitro priming and expansion of cytomegalovirus-specific Th1 and Tc1 T cells from naive cord blood lymphocytes. Blood 2006;108(5):1770-1773